<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600236</url>
  </required_header>
  <id_info>
    <org_study_id>APEC-0018</org_study_id>
    <nct_id>NCT00600236</nct_id>
  </id_info>
  <brief_title>HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population</brief_title>
  <official_title>HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación para Evitar la Ceguera en México</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Nacional de Referencia Epidemiológica (INdRE)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asociación para Evitar la Ceguera en México</source>
  <brief_summary>
    <textblock>
      One of the first causes of irreversible blindness in mexican population is diabetic
      retinopathy which is clearly diferent between patients the time of evolution and development
      of retinopathy and complications. The aim of this study is to explore the inmunogenetic
      profile and the influence of HLA in this variations of the sickness to predict the severity
      of diabetic complications.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood sample</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes mellitus type 2 with 10 years of diagnosis and no diabetic retinopathy

          -  Diabetes mellitus type 2 with 10 years of diagnosis and proliferative retinopathy

        Exclusion Criteria:

          -  Systemic hipertension

          -  Cardic disease

          -  Lupus

          -  Any kind of artritis

          -  Allergies

          -  Optic Neuritis

          -  VKH

          -  Cancer

          -  Inmunological diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugo Quiroz-Mercado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asociación para Evitar la Ceguera en México, Hospital &quot;Luis Sánchez Bulnes&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asociación para Evitar la Ceguera en México, Hospital &quot;Luis Sanchez Bulnes&quot;</name>
      <address>
        <city>Mexico City</city>
        <state>Mexico DF</state>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2006</study_first_submitted>
  <study_first_submitted_qc>January 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2008</study_first_posted>
  <last_update_submitted>January 23, 2008</last_update_submitted>
  <last_update_submitted_qc>January 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2008</last_update_posted>
  <keyword>Diabetes mellitus type 2 with 10 years of diagnosis and no diabetic retinopathy</keyword>
  <keyword>Diabetes mellitus type 2 with 10 years of diagnosis and proliferative diabetic retinopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

